Cancer nanotechnology
Main Article Content
Abstract
maximum therapeutic value and minimum or negligible range side effects. Cancer is the disease in which the abnormal
cells are quite similar to the normal cell with just minute functional or genetic change. Thus, it is very hard to target the
abnormal cells by the conventional method of the drug delivery system. Nanotechnology is probably the only method that
can be used for site-specific action without causing the side effects by killing the normal cells. This review article describes
the possible way to exploit the nanotechnology to targeted drug therapy in cancer. The various methods used are: systemic
delivery systems, passive targeting, active targeting, intracellular delivery, subcellular localization, and nanoparticle drugs.
Different cancer detection techniques like carbon nanotubes, nanorods, and biosensors are also available. This review article
gives an idea about the possible potential of nanotechnology in drug delivery, drug targeting, and the diagnosis of cancer.
Downloads
Article Details
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
References
Alivisatos A. Perspectives on the physical chemistry of semiconductor
nanocrystals. J Phys Chem 1996;100:13226-39.
Suntherland A. Quantum dots as luminescent probes in biological
systems. Curr Opin Solid State Mater Sci 2002;6:36-370.
Perez E. American Pharmaceutical Partners announces presentation of
Abraxane survival data. In: 22nd annual Miami Breast Cancer Conference;
Miami, FL: 2005.
Williams J, Lansdown R, Sweitzer R, Romanowski M, LaBell R,
Ramaswami R, et al. Nanoparticle drug delivery system for
intravenous delivery of topoisomerase inhibitors. J Control Release
;91:167-72.
Leroux JC, Allemann E, De Jaeghere F, Duelker E, Gurny R. Biodegradable
nanoparticles: From sustained release formulation to improved site
specific drug delivery. J Control Release 1996;30:339-50.
Ringdorf H. Structure and properties of pharmacologically active
polymers. J Polym Sci Symp 1975;51:135-53.
Chari RV. Targeted delivery of chemotherapeutics: Tumor-activated
prodrug therapy. Adv Drug Deliv Rev 1998;31:89-104.
Maeda H, Matsumura Y. Tumouritropic and lymphotropic principles of
macromolecular drugs. Crit Rev Ther Drug Carrier Syst 1989;6:193-210.
Ohtsuka N, Konno T, Miyauchi Y, Maeda H. Anticancer effects of arterial
administration of the anticancer agent SMANCS with lipiodol on
metastatic lymph nodes. Cancer 1987;59:1560-5.
Shenoy D, Little S, Langer R, Amiji M. Poly (ethylene oxide) - modified poly
(beta-amino ester) nanoparticles as a pH-sensitive system for tumourtargeted
delivery of hydrophobic drugs: part 2. In vivo distribution and
tumour localization studies. Pharm Res 2005;22:2107-14.
Shenoy D, Little S, Langer R, Amiji M. Poly (ethylene oxide) - modified
poly (beta-amino ester) nanoparticles as a pH-sensitive system for
tumour-targeted delivery of hydrophobic drugs, Part 1: In vitro
evaluations. Mol Pharm 2005;2:357-66.
Shenoy DB, Amiji MM. Poly (ethylene oxide)-modified poly
(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen
in breast cancer. Int J Pharm 2005;293:261-70.
Kommareddy S, Tiwari SB, Amiji MM. Long-circulating polymeric
nanovectors for tumour-selective gene delivery. Technol Cancer Res
Treat 2005;4:615-25.
Kaul G, Amiji M. Long-circulating poly(ethylene glycol)-modified gelatin
nanoparticles for intracellular delivery. Pharm Res 2002;19:1061-7.
Kaul G, Amiji M. Tumour-targeted gene delivery using poly (ethylene
glycol)-modified gelatin nanoparticles: In vitro and in vivo studies. Pharm
Res 2005;22:951-61.
Kaul G, Amiji M. Cellular interactions and in vitro DNA transfection
studies with poly (ethylene glycol)-modified gelatin nanoparticles.
J Pharm Sci 2005;94:184-98.
Kommareddy S, Amiji M. Preparation and evaluation of thiolmodified
gelatin nanoparticles for intracellular DNA delivery in response to
glutathione. Bioconjug Chem 2005;16:1423-32.
Kommareddy S, Amiji M. Poly (ethylene glycol)-modified thiolated
gelatin nanoparticles for glutathione-responsive intracellular DNA
delivery. Nanomedicine 2007;3:32-42.
Kommareddy S, Amiji M. Antiangiogenic gene therapy with systemically
administered sFlt-1 plasmid DNA in engineered gelatin-based
nanovectors. Cancer Gene Ther 2007;14:488-98.
Cegnar M, Kristl J, Kos J. Nanoscale polymer carriers to deliver
chemotherapeutic agents to tumours. Expert Opin Biol Ther
;5:1557-69.
Wagner E. Programmed drug delivery: Nanosystems for tumour
targeting. Exp Opin Biol Ther 2007;7:587-93.
Farokhzad OC, Karp JM, Langer R. Nanoparticle-aptamer bioconjugates
for cancer targeting. Exp Opin Drug Deliv 2006;3:311-24.
Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB,
et al. Antibody targeting of long-circulating lipidic nanoparticles does
not increase tumour localization but does increase internalization in
animal models. Cancer Res 2006;66:6732-40.
Elbayoumi TA, Pabba S, Roby A, Torchilin VP. Anti-nucleosome
antibody-modified liposomes and lipid-core micelles for tumour
targeted delivery of therapeutic and diagnostic agents. J Liposome
Res 2007;17:1-14.
Gupta B, Torchilin VP. Monoclonal antibody 2C5-modified
doxorubicin-loaded liposomes with significantly enhanced therapeutic
activity against intracranial human brain U-87 MG tumour xenografts in
nude mice. Cancer Immunol Immunother 2007;56:1215-23.
Fishman ML, Cooke PH, Coffin DR. Nanostructure of native pectin sugar
acid gels visualized by atomic force microscopy. Biomacromolecules
;5:334-41.
Torchilin VP. Recent approaches to intracellular delivery of drugs and
DNA and organelle targeting. Annu Rev Biomed Eng 2006;8:343-75.
Gupta B, Torchilin VP. Transactivating transcriptional activator mediated
Drug Delivery. Expert Opin Drug Deliv 2006;3:177-90.
Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing:
A formulation approach for poorly-water-soluble compounds. Eur J
Pharm Sci 2003;18:113-20.
Fishman ML, Cooke PH, Coffin DR. Nanostructure of native pectin sugar
acid gels visualized by atomic force microscopy. Biomacromolecules
;5:334-41.
Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms
associated with altered intracellular distribution of anticancer agents.
Pharmacol Ther 2000;85:217-29.
Diaz JF, Strobe R, Engelborghs Y, Souto AA, Andreu JM. Molecular
recognition of Taxol by microtubules kinetics and thermodynamics
of binding of fluorescent Taxol derivatives to an exposed site. J Biol
Chem 2000;275:26265-76.
Nicolaou KC, Riemer C, Kerr MA, Rideout D, Wrasidlo W. Design,
synthesis and biological-activity of protaxols. Nature 1993;364:464-6.
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al.
Circulating tumor cells, disease progression and survival in metastatic
breast cancer. N Engl J Med 2004;351:781-91.
Ellis WJ, Pfitzenmaier J, Colli J, Arfman E, Lange PH, Vessella RL.
Detection and isolation of prostate cancer cells from peripheral blood
and bone marrow. Urology 2003;61: 277-81.
Nam JM, Stoeva SI, Mirkin CA. Bio-bar-code-based DNA detection with
PCR-like sensitivity. J Am Chem Soc 2004;126:5932-3.
Nam JM, Thaxton CS, Mirkin CA. Nanoparticle-based bio-bar codes for
the ultrasensitive detection of proteins. Science 2003;301:1884-6.
Wang WU, Chen C, Lin KH, Fang Y, Lieber CM. Label-free detection of
small-molecule-protein interactions by using nanowire nanosensors.
Proc Natl Acad Sci USA 2005;102:3208-12.
Cui Y, Wei Q, Park H, Lieber CM. Nanowire nanosensors for highly
sensitive and selective detection of biological and chemical species.
Science 2001;293:1289-92.
Hahm J, Lieber CM. Direct ultrasensitive electrical detection of DNA
and DNA sequence variations using nanowire nanosensors. Nano Lett
;4:51-4.
Zheng GF, Patolsky F, Cui Y, Wang WU, Lieber CM. Multiplexed
electrical detection of cancer markers with nanowire sensor arrays.
Nat Biotechnol 2005;23:1294-301.
Wong SS, Joselevich E, Woolley AT, Cheung CL, Lieber CM. Covalently
functionalized nanotubes as nanometre-sized probes in chemistry and
biology. Nature 1998;394:52-5.
Woolley AT, Guillemette C, Cheung CL, Housman DE, Lieber CM. Direct
haplotyping of kilobase-size DNA using carbon nanotube probes. Nat
Biotechnol 2000;18:760-63.
Wang Z, Liu J, Liang Q, Wang Y, Luo G. Carbon nanotube modified
electrodes for the simultaneous determination of dopamine and
ascorbic acid. Analyst 2002;127:653-58.
Wang J, Liu GD, Jan MR. Ultrasensitive electrical biosensing of proteins and DNA: Carbon-nanotube derived amplification of the recognition
and transduction events. J Am Chem Soc 2004;126:3010-1.
Torchilin VP, Levchenko TS, Lukyanov AN, Khaw BA, Klibanov AL,
Rammohan R, et al. P-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and
simple attachment of specific ligands, including monoclonal antibodies,
to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim
Biophys Acta 2001;1511:397-411.
Blume G, Cevc G, Crommelin MD, Bakker-Woudenberg IA, Kluft C,
Storm G. Specific targeting with poly (ethylene glycol)-modified
liposomes: coupling of homing devices to the ends of the polymeric
chains combines effective target binding with long circulation
times. Biochim Biophys Acta 1993;1149:180-4.
Avraham R, James J. Development of biosensors for cancer clinical
testing. Biosensors and Bioelectronics 2006;21:1851-8.